natgillin/translations-raw huggingface dataset:
Neutropenia (< 750 cells/mm3) was reported in 5%, thrombocytopenia (platelets < 50,000/mm3) in 2%, and low haemoglobin (< 8 g/dl) in < 1% of patients receiving Zerit. 
U 5% bolesnika opisana je neutropenija (< 750 stanica/mm3), trombocitopenija (trombociti < 50000/mm3) u 2% bolesnika i snižene vrijednosti hemoglobina (< 8 g/dl) kod < 1% bolesnika koji su primali Zerit.
Very rare (may affect up to 1 in 10,000 people) thrombocytopenia, neutropenia (blood disorders) diabetes mellitus motor weakness (most often reported in the setting of symptomatic hyperlacetatemia or lactic acidosis syndrome) liver failure 
Vrlo rijetke (mogu se javiti u manje od 1 na 10 000 osoba) trombocitopenija, neutropenija (krvni poremećaji) šećerna bolest motorička slabost (najčešće zabilježena u okviru simptomatske hiperlaktatemije ili sindroma laktacidoze) zatajenje jetre
The pharmacokinetics of stavudine was independent of time, since the ratio between AUC(ss) at steady state and the AUC(0-t) after the first dose was approximately 1. 
Farmakokinetika stavudina nije ovisila o vremenu, budući da je omjer AUC(ss) pri stanju dinamičke ravnoteže i AUC(0-t) nakon prve doze bio otprilike 1. Intraindividulane odnosno interindividualne varijacije u farmakokinetičkim značajkama stavudina nakon oralne primjene su male, otprilike 15% odnosno 25%.
The active substance is stavudine (15 mg). 
Djelatna tvar je stavudin (15 mg)
Pancreatitis: patients with a history of pancreatitis had an incidence of approximately 5% onZerit, as compared to approximately 2% in patients without such a history. 
Pankreatitis: Incidencija pankreatitisa u bolesnika koji su prije imali pankreatitis iznosila je od otprilike 5% za vrijeme primjene lijeka Zerit, u usporedbi s incidencijom od otprilike 2% u bolesnika koji nisu imali pankreatitis u anamnezi.
The apparent volume of distribution at steady state is 46±21 l. It was not possible to detect stavudine in cerebrospinal fluid until at least 2 hours after oral administration. 
U cerebrospinalnoj tekućini razine stavudina nije bilo moguće otkriti do najmanje 2 sata nakon oralne primjene.
No significant accumulation of stavudine is observed with repeated administration every 6, 8, or 12 hours. 
Uz ponavljanje primjene svakih 6, 8 ili 12 sati nikakva značajna akumulacija stavudina nije opažena.
Adolescents, children and infants over the age of 3 months: the recommended oral dosage is Patient weight Zerit dosage < 30 kg ≥ 30 kg 
Adolescenti, djeca i dojenčad starija od 3 mjeseca: preporučeno oralno doziranje: Starost bolesnika i/ili težina
15 mg twice daily 15 mg every 24 hours 
15 mg dva puta na dan 15 mg svakih 24 sata
Elimination Following an oral 80-mg dose of 
Nakon oralne primjene 80 mg
20 mg twice daily 20 mg every 24 hours 
20 mg dva puta na dan 20 mg svakih 24 sata
UNIQUE IDENTIFIER - 2D BARCODE Outer carton: 2D barcode carrying the unique identifier included. 
JEDINSTVENI IDENTIFIKATOR - 2D BARKOD Kutija:Sadrži 2D barkod s jedinstvenim identifikatorom.>
For maximum effect, Zerit should be taken on an empty stomach, and preferably at least one hour before a meal. 
Za maksimalan učinak, Zerit bi trebalo uzimati na prazan želudac i to najmanje jedan sat prije jela.
The active substance is stavudine (200 mg). 
Djelatna tvar je stavudin (200 mg)
Zerit is indicated in combination with other antiretroviral medicinal products for the treatment of HIV infected adult patients and paediatric patients (from birth) only when other antiretrovirals can not be used. 
Zerit je indiciran u liječenju odraslih bolesnika i pedijatrijskih bolesnika (od rođenja) zaraženih HIVom u kombinaciji s drugim antiretroviralnim lijekovima samo kad se drugi antiretrovirusni lijekovi ne mogu primjeniti.
Hepatotoxicity and hepatic failure resulting in death were reported during postmarketing surveillance in HIV infected patients treated with antiretroviral agents and hydroxyurea; fatal hepatic events were reported most often in patients treated with stavudine, hydroxyurea and didanosine. 
Hepatotoksičnost i zatajenje jetre sa smrtnim ishodom zabilježeni su tijekom praćenja lijeka nakon stavljanja u promet u bolesnika s infekcijom HIV-om liječenih antiretrovirusnim lijekovima i hidrokarbamidom; smrtni slučajevi zbog zatajenja jetre bili su zabilježeni najčešće u bolesnika liječenih stavudinom, hidrokarbamidom i didanozinom, pa se stoga hidrokarbamid ne smije koristiti tijekom liječenja infekcije HIV-om.
Microcrystalline cellulose 
Magnezijev stearat Mikrokristalična celuloza Natrijev škroboglikolat
The duration of therapy with Zerit should be limited to the shortest time possible (see section 
Trajanje terapije lijekom Zerit trebalo bi ograničiti na najmanje moguće vrijeme (vidjeti dio 4.2).
Each hard capsule contains 79.53 mg of lactose monohydrate. 
Jedna tvrda kapsula sadrži 79,53 mg laktoze hidrata.
Lipoatrophy: on the basis of mitochondrial toxicity stavudine has been shown to cause loss of subcutaneous fat, which is most evident in the face, limbs and buttocks. 
Lipoatrofija:temeljeno na mitohondrijskoj toksičnosti pokazano je da stavudin uzrokuje gubitak subkutane masnoće osobito na licu, udovima i stražnjici.
However, lactic acidosis, sometimes fatal, has been reported in pregnant women who received the combination of didanosine and stavudine with or without other anti-retroviral treatment (see sections 4.3 and 4.4). 
Međutim, ponekad kobna laktična acidoza opisana je u trudnica koje su primale kombinaciju didanozina i stavudina sa ili bez ostale antiretrovirusne terapije (vidjeti dio 4.3 i 4.4).
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON TEXT (BLISTER) 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU TEKST NA KUTIJA (BLISTERU)
1 mg/kg twice daily (every 12 hours) adult dosing 
1 mg/kg dva puta dnevno (svakih 12 sati) doziranje za odrasle
The powder formulation of ZERIT should be used for infants under the age of 3 months. 
Pripravak lijeka Zerit u obliku praška primjenjuje se u dojenčadi starosti do 3 mjeseca.
The powder formulation of Zerit should be used for infants under the age of 3 months. 
Pripravak lijeka ZERIT u obliku praška primjenjuje se u dojenčadi starosti do 3 mjeseca.
Rare (may affect up to 1 in 1,000 people) anemia hyperglycaemia (high sugar levels in the blood) hepatic steatosis (fat in the liver) 
Rijetko (mogu se javiti u 1 na 1000 osoba) anemija hiperglikemija (visoka razina šećera u krvi) hepatička steatoza (masna jetra)
Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement. 
Bolesnicima treba savjetovati da u slučaju bolova u zglobovima, ukočenosti zglobova ili otežanog kretanja potraže liječničku pomoć.
Propylene Glycol 
Propilenglikol
Metabolic parameters: weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section 4.4). 
Metabolički parametri: tijekom antivirusne terapije mogu se povećati tjelesna težina i povisiti razine lipida i glukoze u krvi (vidjeti dio 4.4).
Black ink containing 
Crna tinta sadrži:
Stavudine therapy is associated with several severe side effects, such as lactic acidosis, lipoatrophy and polyneuropathy, for which a potential underlying mechanism is mitochondrial toxicity. 
Terapija stavudinom povezana je s nekoliko teških nuspojava, kao što su laktična acidoza, lipoatrofija i polineuropatija, čiji je mogući podležeći mehanizam nastanka mitohondrijska toksičnost.
Dual energy x-ray absorptiometry (DEXA) scans demonstrated overall limb fat loss in stavudine treated patients compared to limb fat gain or no change in patients treated with other NRTIs (abacavir, tenofovir or zidovudine). 
Mjerenja dvoenergijskom rengenskom denzitometrijom (DEXA) obično bi pokazala gubitak masnog tkiva na udovima u bolesnika liječenih stavudinom za razliku od povećanja masnog tkiva na udovima ili izostanak ikakve promjene u masnom tkivu u bolesnika liječenih drugim nukleozidnim inhibitorima reverzne transkriptaze (NRTI, engl. nucleoside reverse transcriptase inhibitor) (abakavirom, tenofovirom ili zidovudinom).
Also listed are adverse reactions observed post-marketing in association with stavudine-containing antiretroviral treatment. 
Navedene su i nuspojave primijećene u razdoblju nakon stavljanja lijeka u promet koje su bile povezane s antiretrovirusnim terapijskim režimima koji su uključivali stavudin.
Stavudine, a thymidine analogue, is phosphorylated by cellular kinases to stavudine triphosphate which inhibits HIV reverse transcriptase by competing with the natural substrate, thymidine triphosphate. 
Stavudin, analog timidina, je fosforiliran putem stanične kinaze do stavudin trifosfata, koji inhibira reverzibilnu transkriptazu HIV-a tako što se natječe s prirodnim supstratom, timidin trifosfatom.Također inhibira sintezu virusne DNA tako što uzrokuje završetak DNA lanca uslijed nedostatka 3′-hidroksilne skupine koja je potrebna za produženje DNA.
Zerit 15 mg hard capsules are red and yellow and marked with “BMS 1964” on one side and “15” on the other side. 
Zerit 15 mg tvrde kapsule su crvene i žute boje, označene s “BMS 1964” na jednoj i “15” na drugoj polovici.
Uncommon (may affect up to 1 in 100 people) lactic acidosis (build up of acid in your blood) in some cases involving motor weakness (weakness in your arms, legs or hands) gynaecomastia (breast enlargement in men) anorexia (loss of appetite), anxiety, emotional lability pancreatitis (inflammation of the pancreas), vomiting hepatitis (inflamation of the liver), jaundice (yellow of the skin or eyes) urticaria (itchy rash), arthralgia (joint pain) myalgia (aching muscles), asthenia (unusual tiredness or weakness) 
Manje često (mogu se javiti u manje od 1 na 100 osoba) laktacidoza (nakupljanje kiseline u krvi) koja u nekim slučajevima uključuje i motoričku slabost (slabost u rukama, nogama ili šakama) ginekomastija (povećanje grudi u muškaraca) anoreksija (gubitak apetita), tjeskoba, emocionalna labilnost pankreatitis (upala gušterače), povraćanje hepatitis (upala jetre), žutica (žuta boja kože ili očiju) urtikarija (osip sa svrbežom), artralgija (bolnost zglobova) mialgija (bolovi u mišićima), astenija (neuobičajeni umor ili slabost)
15 mg twice daily 
15 mg dva puta dnevno
MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
A PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA U PROMET
It is recommended that HIV-infected women should not breast-feed under any circumstances in order to avoid transmission of HIV to the baby. 
Preporuča se da žene zaražene HIV-om ni pod kojim okolnostima ne bi smjele dojiti, kako bi se izbjegao prijenos HIV-a na dojenče.
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4). 
Međutim, prijavljeno vrijeme početka tih poremećaja je vrlo varijabilno jer se oni mogu pojaviti i nekoliko mjeseci nakon početka liječenja.(vidjeti dio 4.4).
common: rash, pruritus uncommon: urticaria 
često: osip, pruritus manje često: urtikarija
Zerit 20 mg hard capsules are brown and marked with “BMS 1965” on one side and “20” on the other side. 
Zerit 20 mg tvrde kapsule su smeđe boje, označene s “BMS 1965” na jednoj i “20” na drugoj polovici.
OF THE REACH AND SIGHT OF CHILDREN Keep out of the sight and reach of children. 
Čuvati izvan pogleda i dohvata djece.
Do not use this medicine after the expiry date which is stated on the carton, the bottle label and/or the blister after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji, naljepnici boce i/ili blisteru iza oznake “Rok valjansti”/EXP.
Lipoatrophy was commonly reported in patients treated with stavudine in combination with other antiretrovirals (see section 4.4). 
Lipoatrofija često je bila zabilježena u bolesnika liječenih stavudinom u kombinaciji s drugim antiretrovirusnim lijekovima (vidjeti dio 4.4).
Zerit 200 mg powder for oral solution Stavudine 
Zerit 200 mg prašak za oralnu otopinu stavudin
HIV RNA Mean Change from Baseline, log10 copies/ml All patients 
HIV RNA srednja promjena u odnosu na početnu vrijednost, log10 kopija/ml
Excipients: the reconstituted powder for oral solution contains 50 mg sucrose per ml of reconstituted solution. 
Pomoćne tvari: rekonstituirani prašak za oralnu otopinu sadrži 50 mg saharoze po ml rekonstituirane otopine.To treba uzeti u obzir kod bolesnika sa šećernom bolesti.
Each hard capsule contains 60.66 mg of lactose monohydrate. 
Jedna tvrda kapsula sadrži 60,66 mg laktoze hidrata.
Each hard capsule contains 40.42 mg of lactose monohydrate. 
Jedna tvrda kapsula sadrži 40,42 mg laktoze hidrata.
Lipoatrophy: stavudine has been shown to cause loss of subcutaneous fat, which is most evident in the face, limbs and buttocks. 
Lipoatrofija: pokazalo se da stavudin uzrokuje gubitak potkožnog masnog tkiva koji je najočitiji na licu, udovima i stražnjici.
Zerit 30 mg hard capsules are light and dark orange and marked with “BMS 1966” on one side and “30” on the other side. 
Zerit 30 mg tvrde kapsule su svijetlo i tamno narančaste boje, označene s “BMS 1966” na jednoj i “30” na drugoj polovici.
NAME OF THE MEDICINAL PRODUCT Zerit 200 mg powder for oral solution Stavudine 
NAZIV LIJEKA Zerit 200 mg prašak za oralnu otopinu stavudin
Iron oxide colorant (E172) 
Pročišćenu vodu, pročišćenu Kalijev hidroksid Željezov oksid (E172)
NAME OF THE MEDICINAL PRODUCT Zerit 200 mg powder for oral solution 
NAZIV LIJEKA Zerit 200 mg prašak za oralnu otopinu
Zerit 40 mg hard capsules are dark orange and marked with “BMS 1967” on one side and “40” on the other side. 
Zerit 40 mg tvrde kapsule su tamno narančaste boje, označene s “BMS 1967” na jednoj i “40” na drugoj polovici.
There are no dosage recommendations for paediatric patients under the age of 3 months with renal impairment. 
U pedijatrijskih bolesnika starosti do 3 mjeseca s oštećenjem bubrega ne postoje preporuke za doziranje.
Cmax and AUC increased proportionally with dose in the dose ranges, intravenous 0.0625-0.75 mg/kg, and oral 0.033-4.0 mg/kg. 
U rasponu doza od 0,0625-0,75 mg/kg intravenski i od 0,033-4,0 mg/kg oralno, vrijednosti Cmax i AUC rasle su proporcionalno s dozom.
B CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2). 
Lijek se izdaje na ograničeni recept (Vidjeti Prilog I: Sažetak opisa svojstava lijeka, dio 4.2).
STATEMENT OF ACTIVE SUBSTANCE(S) Each bottle contains stavudine 200 mg The reconstituted solution contains 1 mg of stavudine per ml. 
2. NAVOĐENJE DJELATNE (IH) TVARI Jedna boca sadrži 200 mg stavudina.
20 mg twice daily 
20 mg dva puta dnevno
Capsule shell 
Ovojnica kapsule:
Study AI455-099 was a 48-week, randomised, double-blind study withZerit (40 mg twice daily), in combination with lamivudine (150 mg twice daily) plus efavirenz (600 mg once daily), in 391 treatment-naive patients, with a median CD4 cell count of 272 cells/mm (range 61 to 1,215 cells/mm3) and a median plasma HIV-1 RNA of 4.80 log10 copies/ml (range 2.6 to 5.9 log 10 copies/ml) at baseline. 
Ispitivanje AI455-099 je trajalo 48 tjedana, bilo je randomizirano, dvostruko slijepo ispitivanje s lijekom Zerit (40 mg dva puta dnevno) u kombinaciji s lamivudinom (150 mg dva puta dnevno) i efavirenzom (600 mg jednom dnevno), u 391 bolesnika koji prethodno nisu bili liječeni, s početnim medijanom vrijednosti CD4 stanica od 272 stanica/mm3 (raspon od 61 do 1215 stanica/mm3) i početnim medijanom vrijednosti HIV-1 RNA u plazmi od 4,80 log10 kopija/ml (raspon 2,6 do 5,9 log10 kopija/ml).
The hard capsule is red and yellow, opaque and imprinted with “BMS” over a BMS code “1964” on one side and “15” on the other side. 
Crvena i žuta tvrda neprozirna kapsula, s otisnutim “BMS” iznad BMS koda “1964” s jedne i “15” s druge strane.
In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects. 
U djece čije su majke tijekom trudnoće uzimale nukleozidne inhibitore reverzne transkriptaze (NRTI), korist zaštite od HIV-a nadmašuje rizik od nuspojava.
Each hard capsule contains 121.09 mg of lactose anhydrous. 
Jedna tvrda kapsula sadrži 121,09 mg laktoze, bezvodne.
You must contact your doctor to discuss the potential side effects and the benefits and risks of your antiretroviral therapy to you and your child. Lactic acidosis (sometimes fatal) has been reported in pregnant women who received Zerit in combination with other antiretroviral treatment. 
Morate se javiti Vašem liječniku kako biste raspravili moguće nuspojave te koristi i rizike Vašeg antiretrovirusne terapije za Vas i Vaše dijete.
Tell your doctor if you notice any loss of fat from your legs, arms, and face. 
Ako primijetite bilo kakav gubitak masnog tkiva u Vašim nogama, rukama i licu, obavijestite o tome svog liječnika.
The hard capsule is brown, opaque and imprinted with “BMS” over a BMS code “1965” on one side and “20” on the other side. 
Smeđa tvrda neprozirna kapsula, s otisnutim “BMS” iznad BMS koda “1965” s jedne i “20” s druge strane.
Zerit 15 mg hard capsules 
Zerit 15 mg tvrde kapsule
Capsule contents 
Sadržaj kapsule:
INFORMATION IN BRAILLE Zerit 15 mg 
16. PODACI NA BRAILLEOVOM PISMU Zerit 15 mg
Each hard capsule contains 159.06 mg of lactose anhydrous. 
Jedna tvrda kapsula sadrži 159,06 mg laktoze, bezvodne.
Each hard capsule contains 60.54 mg of lactose monohydrate. 
Jedna tvrda kapsula sadrži 60,54 mg laktoze hidrata.
Stearate emulsifiers Sucrose 
Karmeloza-natrij Sorbatna kiselina Stearatni emulgatori Saharoza
Do not use this medicine after the expiry date which is stated on the bottle and on the carton after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na boci i kutiji iza oznake“Rok valjanosti”.
The hard capsule is light and dark orange, opaque and imprinted with “BMS” over a BMS code “1966” on one side and “30” on the other side. 
Svijetlo i tamno narančasta tvrda neprozirna kapsula, s otisnutim “BMS” iznad BMS koda “1966” s jedne i “30” s druge strane.
INFORMATION IN BRAILLE Zerit 20 mg 
16. PODACI NA BRAILLEOVOM PISMU Zerit 20 mg
PHARMACEUTICAL FORM AND CONTENTS Powder for oral solution, 200 mg 
Prašak za oralnu otopinu, 200 mg
Study AI455-096 was a 48-week, randomised, double-blind study with Zerit (40 mg twice daily), in combination with lamivudine (150 mg twice daily) plus efavirenz (600 mg once daily), in 76 treatment-naive patients, with a median CD4 cell count of 261 cells/mm3 
Ispitivanje AI455-096 je trajalo 48 tjedana, bilo je randomizirano, dvostruko slijepo ispitivanje s lijekom Zerit (40 mg dva puta dnevno), u kombinaciji s lamivudinom (150 mg dva puta dnevno) i efavirenzom (600 mg jednom dnevno), u 76 bolesnika koji prethodno nisu bili liječeni, s početnim medijanom vrijednosti CD4 stanica od 261 stanica/mm
It is recommended that HIV infected women should not breast-feed under any circumstances in order to avoid transmission of HIV. 
Ne preporuča se da žene koje imaju infekciju HIV-om doje ni pod kojim uvjetima kako bi se izbjeglo prijenos HIV virusa na dijete.
Aclar/aluminum blisters with 14 hard capsules per card and 4 cards (56 hard capsules) per carton. 
HDPE boce sa sigurnosnim zatvaračem za djecu s navojem (60 tvrdih kapsula u boci), Aclar/aluminij blisteri s 14 tvrdih kapsula po blisteru i 4 blistera (56 tvrdih kapsula) u kutiji.
LIST OF EXCIPIENTS Lactose 
3. POPIS POMOĆNIH TVARI Laktoza
Bristol-Myers Squibb S.r.l. 
SQUIBB S.R.L.
Please refer to the Summary of Product Characteristics of the powder formulation. 
Vidjeti Sažetak opisa svojstava lijeka za pripravak u obliku praška.
Each hard capsule contains 80.84 mg of lactose anhydrous. 
Jedna tvrda kapsula sadrži 80,84 mg laktoze, bezvodne.
INFORMATION IN BRAILLE Outer carton: Zerit 200 mg 
16. PODACI NA BRAILLEOVOM PISMU Kutija: Zerit 200 mg
The hard capsule is dark orange, opaque and imprinted with “BMS” over a BMS code “1967” on one side and “40” on the other side. 
Tamno narančasta tvrda neprozirna kapsula, s otisnutim “BMS” iznad BMS koda “1967” s jedne i “40” s druge strane.
INFORMATION IN BRAILLE Zerit 40 mg 
16. PODACI NA BRAILLEOVOM PISMU Zerit 40 mg
Each hard capsule contains 121.30 mg of lactose anhydrous. 
Jedna tvrda kapsula sadrži 121,30 mg laktoze, bezvodne.
Titanium dioxide (E171) 
Boja željezov oksid (E172) Silicijev dioksid Natrijev laurilsulfat Titanijev dioksid (E171)
Common (may affect up to 1 in 10 people) asymptomatic hyperlactatemia (build up of acid in your blood) lipoatrophy depression peripheral neurologic symptoms including peripheral neuropathy, paresthesia, and peripheral neuritis (numbness, weakness, tingling or pain in the arms and legs) dizziness, abnormal dreams, headache insomnia (difficulty sleeping), somnolence (sleepiness), abnormal thinking diarrhoea, abdominal pain (stomach pain of discomfort) nausea, dyspepsia (indigestion) rash, pruritus (itching) fatigue (extreme tiredness) 
Često (mogu se javiti u 1 na 10 osoba) asimptomatska hiperlaktatemija (nakupljanjekiseline u krvi) sindrom lipoatrofije depresija periferni neurološki simptomi uključujući perifernu neuropatiju, parestezije i periferni neuritis (utrnutost, slabost, trnci ili bolovi u rukama i nogama) omaglica, abnormalni snovi, glavobolja nesanica (poteškoće sa spavanjem), somnolencija (jaka pospanost), abnormalne misli proljev, bolovi u trbuhu (bolovi i nelagoda u želucu) mučnina, dispepsija (probavne smetnje) osip, pruritus (svrbež) umor (krajnje izražen umor)
INFORMATION IN BRAILLE Zerit 30 mg 
16. PODACI NA BRAILLEOVOM PISMU Zerit 30 mg
Zerit 20 mg hard capsules Each hard capsule contains 20 mg of stavudine. 
Jedna tvrda kapsula sadrži 20 mg stavudina.
Magnesium stearate 
Mouće nuspojave
Zerit 20 mg hard capsules 
Zerit 20 mg tvrde kapsule
Zerit 15 mg hard capsules Stavudine 
Zerit 15 mg tvrde kapsule stavudin
Zerit 30 mg hard capsules 
Zerit 30 mg tvrde kapsule
Replace the cap. 
Vratite zatvarač.
The other ingredients of the powder are: cherry flavour, methylhydroxybenzoate (E218), propylhydroxybenzoate (E216), silicon dioxide, simethicone, sodium carmellose, sorbic acid, stearate emulsifiers and sucrose. 
(E216), silicijev dioksid, simetikon, karmeloza natrij, sorbatna kiselina, stearatni emulgator i saharoza.
Zerit 40 mg hard capsules 
Zerit 40 mg tvrde kapsule
Zerit 15 mg hard capsules Each hard capsule contains 15 mg of stavudine. 
Jedna tvrda kapsula sadrži 15 mg stavudina.
Zerit 20 mg hard capsules Stavudine 
Zerit 20 mg tvrde kapsule stavudin
INFORMATION IN BRAILLE Outer carton: Zerit 15 mg 
16. PODACI NA BRAILLEOVOM PISMU Kutija: Zerit 15 mg
Zerit 40 mg hard capsules Each hard capsule contains 40 mg of stavudine. 
Jedna tvrda kapsula sadrži 40 mg stavudina.
Zerit 30 mg hard capsules Stavudine 
Zerit 30 mg tvrde kapsule stavudin
OUTER CARTON TEXT AND BOTTLE LABEL TEXT (BOTTLE PRESENTATION) 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM I UNUTARNJEM PAKIRANJU TEKST NA KUTIJI I NALJEPNICI NA BOCI (PAKIRANJE S BOCOM)
INFORMATION IN BRAILLE Outer carton: Zerit 20 mg 
16. PODACI NA BRAILLEOVOM PISMU Kutija: Zerit 20 mg
Zerit 30 mg hard capsules Each hard capsule contains 30 mg of stavudine. 
Jedna tvrda kapsula sadrži 30 mg stavudina.
Zerit 40 mg hard capsules Stavudine 
Zerit 40 mg tvrde kapsule stavudin
INFORMATION IN BRAILLE Outer carton: Zerit 30 mg 
16. PODACI NA BRAILLEOVOM PISMU Kutija: Zerit 30 mg
STATEMENT OF ACTIVE SUBSTANCE(S) Each hard capsule contains 20 mg stavudine. 
2. NAVOĐENJE DJELATNE (IH) TVARI Jedna tvrda kapsula sadrži 20 mg stavudina.
INFORMATION IN BRAILLE Outer carton: Zerit 40 mg 
16. PODACI NA BRAILLEOVOM PISMU Kutija: Zerit 40 mg
STATEMENT OF ACTIVE SUBSTANCE(S) Each hard capsule contains 15 mg stavudine. 
2. NAVOĐENJE DJELATNE (IH) TVARI Jedna tvrda kapsula sadrži 15 mg stavudina.
STATEMENT OF ACTIVE SUBSTANCE(S) Each hard capsule contains 30 mg stavudine. 
2. NAVOĐENJE DJELATNE(IH) TVARI Jedna tvrda kapsula sadrži 30 mg stavudina.